Why Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?

MediciNova Inc's MNOV collaborators presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the Annual Meeting of the Society for Neuro-Oncology. The primary endpoints of this Phase 2 clinical trial were the safety and tolerability of…#medicinovainc #gbm #phase2 #rano #immunohistochemistry #cd3expression #tmz #p005 #median
Source: Reuters: Health - Category: Consumer Health News Source Type: news